SCHEMBL8937620

SCHEMBL8937620

COc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccc(OC)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.79
L3MBTL1 Q9Y468 1/20 0.79
CYP1A2 P05177 1/20 0.61
POLB P06746 1/20 0.59
GAA P10253 1/20 0.55
GPR183 P32249 1/20 0.54
TUBB4A P04350 1/20 0.53
TUBB P07437 1/20 0.53
TUBA3C P0DPH7 1/20 0.53
TUBA1B P68363 1/20 0.53
TUBA4A P68366 1/20 0.53
TUBB4B P68371 1/20 0.53
TUBB3 Q13509 1/20 0.53
TUBB2A Q13885 1/20 0.53
TUBB8 Q3ZCM7 1/20 0.53
TUBA3E Q6PEY2 1/20 0.53
TUBA1A Q71U36 1/20 0.53
TUBA1C Q9BQE3 1/20 0.53
TUBB6 Q9BUF5 1/20 0.53
TUBB2B Q9BVA1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937251 0.95 ALDH1A1 (0.72) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937249 0.95 ALDH1A1 (0.72) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937244 0.95 ALDH1A1 (0.72) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937435 0.93 ALDH1A1 (0.69) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937440 0.93 ALDH1A1 (0.69) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937224 0.92 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937225 0.92 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937483 0.92 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937481 0.92 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937354 0.92 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed